Panelists discuss best practices for patient education and engagement when introducing CDK4/6 inhibitors in metastatic breast cancer care.

Panelists discuss the long-term safety and durability of CDK4/6 inhibitors, highlighting data supporting sustained efficacy and manageable toxicity over years of treatment.

Panelists review key trial data that reinforce the value of CDK4/6 inhibitors in metastatic breast cancer and discuss implications for clinical practice.

Panelists discuss insights from real-world data on CDK4/6 inhibitor use, including outcomes across diverse populations and clinical settings.

Panelists discuss emerging clinical studies exploring innovative combinations and next-generation approaches to enhance CDK4/6 inhibitor efficacy.

Panelists explore how future research may expand the role of CDK4/6 inhibitors across treatment settings and patient populations.

Panelists discuss sequencing strategies for CDK4/6 inhibitors and the clinical factors influencing order of therapy in metastatic breast cancer.

Panelists discuss the importance of clinical trial end points, survival outcomes, and guideline recommendations in guiding CDK4/6 inhibitor use.

Panelists discuss how to manage adverse events associated with CDK4/6 inhibitors and ensure smooth care transitions across health care settings.

Panelists discuss broader clinical issues such as resistance, treatment duration, and quality of life in patients receiving CDK4/6 inhibitors.

Panelists discuss practical strategies to overcome barriers to initiating and maintaining CDK4/6 inhibitor therapy.

Panelists discuss how coordinated multidisciplinary care improves adherence to oral targeted therapy.

Panelists discuss how technology—including digital tools and artificial intelligence—can monitor and improve adherence to CDK4/6 inhibitor therapy.